Screener
CRISPR Therapeutics CRSP Income Tax
Income Tax at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:48 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204188
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Other income, net | 8,156 | 13,537 |
| Total other income, net | 8,156 | 13,537 |
| Net loss before income taxes | (122,092) | (134,887) |
| Provision for income taxes | (839) | (1,109) |
| Net loss | (122,931) | (135,996) |
| Foreign currency translation adjustment | (32) | 41 |
| Unrealized (loss) gain on marketable securities | (6,730) | 2,254 |
| Comprehensive loss | $(129,693) | $(133,701) |
Item 1. Financial Statements
FAQ
- What is CRISPR Therapeutics's income tax?
- CRISPR Therapeutics (CRSP) reported income tax of $839K in Q1 2026.
- How has CRISPR Therapeutics's income tax changed year-over-year?
- CRISPR Therapeutics's income tax decreased by 24.3% year-over-year, from $1.11M to $839K.
- What is the long-term trend for CRISPR Therapeutics's income tax?
- Over 3 years (2022 to 2025), CRISPR Therapeutics's income tax has grown at a 123.6% compound annual growth rate (CAGR), from -$325K to $3.63M.
- What does income tax mean?
- Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.
Ask your AI about CRISPR Therapeutics's income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude